Evidence map›Paper›PMID 28448570›Full record

ArticlePloS one2017

Disease burden for patients with primary immunodeficiency diseases identified at reference hospitals in Guanajuato, Mexico.

Eduardo Guaní-Guerra, Ana Isabel Jiménez-Romero, Ulises Noel García-Ramírez, José Manuel Velázquez-Ávalos, Edgar Martínez-Guzmán, Eunice Sandoval-Ramírez, Ignacio Camacho-Meza

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. The presence of overlapping quality of life symptoms in primary antibody deficiency (PAD) and chronic fatigue syndrome (CFS).Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2020
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Eduardo Guaní-GuerraDepartment of Immunology, Hospital Regional de Alta Especialidad del Bajío, León Guanajuato, México.ORCID http://orcid.org/0000-0001-6494-5511
Ana Isabel Jiménez-RomeroDepartament of Immuno-Allergology Pediatrics, Hospital Ángeles-León, León Guanajuato, México.
Ulises Noel García-RamírezDepartment of Immuno-Allergology, Centro Médico Nacional del Bajío, IMSS, León Guanajuato, México.
José Manuel Velázquez-ÁvalosDepartment of Immuno-Allergology, Centro Médico Nacional del Bajío, IMSS, León Guanajuato, México.
Edgar Martínez-GuzmánDepartment of Immunology, Hospital Regional de Alta Especialidad del Bajío, León Guanajuato, México.
Eunice Sandoval-RamírezDepartment of Immuno-Allergology Pediatrics, Hospital Pediátrico de León, León Guanajuato, México.
Ignacio Camacho-MezaDepartment of Immuno-Allergology Pediatrics, Hospital Pediátrico de León, León Guanajuato, México.
Hospital de León · ESCentro Medico Nacional Siglo XXI · MXHospital de La Ribera · ESHospital Regional de Alta Especialidad del Bajío · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn addition to the deleterious effect on health, there is considerable economic and psychosocial morbidity associated with primary immunodeficiency diseases (PID). Also, the cost of a late diagnosis frequently results in a heavy disease burden on the patient. The objective of this study was to collect and analyze data on patients with PID in the state of Guanajuato in Mexico, to indirectly estimate the burden of the disease.

methodsAn observational, longitudinal, and comparative study was conducted. A total of 44 patients were included and grouped according to the updated classification of PID.

resultsThe median time elapsed from the onset of symptoms to the reference and diagnosis by a tertiary hospital was of 2.17 (IQR = 6.44) years. Before diagnosis, the number of hospitalizations/year per patient was 0.86 (IQR = 2.28), the number of visit to emergency room/year per patient was 0.92 (IQR = 1.77), the number of doctor's visits/year per patient was 15 (IQR = 11.25), whereas the school/work absence days per patient were reported in 52.72 (IQR = 56.35) days per year. After diagnosis, 20 patients (45.45%) received IVIG replacement therapy, and all of them presented a significant improvement (p <0.05) in all the mentioned variables. Characteristically, even when patients with PID received IVIG, there was still an important disease burden when comparing them against healthy controls. Complications secondary to PID were detected in 19 patients (43.18%). The reported overall mortality rate was 6.82% (n = 3).

conclusionsWe were able to indirectly estimate an important disease burden in patients with PID; which is considered to be preventable, at least in part, with effective interventions like health planning, research, collaboration with primary care providers, and generation of policies and practices, in order to improve the quality of life and care of families with PID.

Indexed as

Cost of IllnessAdolescentAdultCase-Control StudiesChildChild, PreschoolEmergency Service, HospitalFemaleHospitalizationHumansImmunoglobulins, IntravenousImmunologic Deficiency SyndromesInfantLongitudinal StudiesMaleMexicoImmunoglobulins, Intravenous

Identifiers

PMID28448570
PMCPMC5407621
OpenAlexW2608782924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.